Delivery Order SPE2DB22D9239-SPE2DB26FDD71
- Not listed
- The Defense Logistics Agency awarded a $27,343.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, represents a focused procurement action without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The Defense Logistics Agency awarded a $31,900.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, an oncology treatment medication. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award...
- The Defense Logistics Agency (DLA), operating under the Medical Supply Chain, awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc. on September 16, 2025, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order is scheduled for completion by October 7, 2025, with performance taking place at the contractor's location in Park Ridge, Illinois. The award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete directly...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $13,671.78 by the Defense Logistics Agency on August 6, 2025, with an ultimate completion date of August 27, 2025. The delivery order covers Perjeta 420 mg/14 mL vials, an oncology treatment medication, with no set-aside designation applied. This award was issued under DMS Pharmaceutical Group's existing single-award...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc. on September 22, 2025, for the supply of Perjeta 420 mg/14 mL vials totaling $27,343.62 with firm fixed pricing. This delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA valued at $499,999,999 and effective through November 2026. The award carries no set-aside designation and requires completion by October 14, 2025, with performance based in Park Ridge,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $63,801.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a specific supply requirement fulfilled under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $41,015.34 by the Defense Logistics Agency's Medical Supply Chain on August 18, 2025. The delivery order, which concludes on September 9, 2025, calls for the supply of Perjeta 420 mg/14 mL vials to support Department of Defense healthcare requirements. This award was issued without a set-aside designation, allowing DMS...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The contract, awarded on September 15, 2025, carries a ceiling value of $27,343.62 and utilizes firm fixed-price pricing with an ultimate completion date of October 6, 2025. This delivery order was issued without a set-aside designation, enabling DMS Pharmaceutical Group to...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge facility with an ultimate completion date of October 10, 2025. The award was issued on September 19, 2025, without a set-aside designation, allowing...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB26FDD71Delivery Order
The Defense Logistics Agency awarded a $77,830.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order was issued on October 20, 2025, with an ultimate completion date of November 10, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award falls under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity spanning oncology treatments, immunosuppressants, biologics, vaccines, and specialty pharmaceuticals. The company's single-award IDC under PPV-G GEN V, valued at $499,999,999 through December 31, 2036, positions it as a regional prime vendor contractor authorized to supply diverse pharmaceutical products to military healthcare facilities worldwide. The contractor's demonstrated performance across multiple therapeutic categories and product lines supports its role in fulfilling the specialized pharmaceutical requirements of the Department of Defense's global medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $77.8k | 10/20/25 |